The leaders of Bristol-Myers Squibb are hoping that Opdivo and Eliquis will each generate multi-billion sales growth for years to come.
Sovaldi and Harvoni have transformed Gilead – but what’s next now that both have likely passed their peak?
GlaxoSmithKline continues to accelerate new product sales momentum and bolster the company’s pharmaceuticals, vaccines and consumer healthcare businesses.
To meet performance objectives, J&J developed a set of near-term priorities for each business segment that will allow the company to achieve long-term growth.
The “YZ” years have been difficult for Lilly, but signs of new growth may be percolating below the surface.
Merck’s newest immuno-oncologic is providing much-needed hope to a portfolio full of stagnant sales numbers.
With a strategic focus on science-based innovation, Novartis is well-positioned to navigate the challenging healthcare environment and sustainably grow sales, profits and dividends.
Despite the growing prevalence of diabetes and a need for new treatments, Novo Nordisk faces tougher times because of reimbursement issues and will also be working with a new leader.
Though Pfizer failed to acquire Allergan and decided against splitting into two separate companies, the company has made several other acquisitions in 2015 and 2016 and continues to expand its pipeline.
Successful R&D of new tests and medicines and improving access to the company’s medical solutions are key to the sustainable development of Roche’s business.
